Related Experiment Videos

Beta blocker specificity: a building block toward personalized medicine

Brent R DeGeorge1, Walter J Koch

  • 1Center for Translational Medicine and George Zallie and Family Laboratory for Cardiovascular Gene Therapy, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

The Journal of Clinical Investigation
|January 4, 2007
PubMed

Insights

Genetic variations in beta-1 adrenergic receptors (beta-AR) influence heart failure patient responses to beta blockers. A specific amino acid change enhances receptor function and carvedilol effectiveness, paving the way for personalized medicine.

Area of Science:

  • Pharmacology
  • Cardiology
  • Genetics

Background:

  • Beta blockers are crucial for treating chronic heart failure (HF).
  • Patient responses to beta blockers vary significantly.
  • Genetic differences in beta-1 adrenergic receptors (beta-AR) are implicated in this variability.

Purpose of the Study:

  • To investigate how a specific genetic variation in beta-1 AR affects patient response to beta blockers.
  • To understand the mechanistic basis for variable responses to carvedilol in heart failure.

Main Methods:

  • The study focused on a single amino acid change in the beta-1 AR.
  • Analysis of structural conformation and functional response to carvedilol.

Main Results:

  • A single amino acid alteration in beta-1 AR was found to modify its structural conformation.
  • This change improved the receptor's functional response to the beta blocker carvedilol.
  • The findings offer a potential explanation for differential patient responses to carvedilol and other beta blockers.

Conclusions:

  • Genetic heterogeneity of beta-1 AR influences therapeutic outcomes in heart failure patients.
  • Understanding these genetic factors can lead to personalized medicine approaches.
  • Tailored therapies based on patient genotype may optimize beta blocker treatment for heart failure.

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...